IVI in the Media

EIU Perspectives | What does Denmark’s permanent suspension of both the AstraZeneca and Janssen covid-19 vaccines mean for other countries?

Asia Times | Vaccinations in a race against viral variants

Nature | Why COVID vaccines are so difficult to compare

DEVEX | Opinion: COVAX — too big, and too important, to fail

CNN | “Our response needs to be clear, strong, and unified”

South China Morning Post | Coronavirus vaccines will save 2021? Not so fast, here’s what the experts think

Bloomberg | Will the Covid-19 Vaccines Be Effective and Safe?

Asian Boss | Update On COVID-19 Vaccine Price & Schedule From A Leading Vaccine Expert

The Telegraph | ‘If you are not prepared, the virus has found every weakness’: How countries in Asia tamed Covid-19

CGTN | ‘The vaccine itself is not the silver bullet,’ says International Vaccine Institute

Devex | Q&A: Why Jerome Kim is ‘hopeful’ but cautious about distributing a COVID-19 vaccine

Maeil Business Newspaper | IVI Director General Jerome Kim Shares His Thoughts on Resurgence of COVID-19 Outbreaks in S. Korea

Chosun Ilbo | IVI Director General Jerome Kim Shares His Thoughts on Equitable Access of COVID-19 Vaccines

Channel News Asia | On a fast track like never before: The COVID-19 vaccine effort and 5 vital questions

The Economist’s Future of Healthcare Insight Hour | Vaccine development: A race to the finish line

Devex | Q&A: Is COVID-19 helping or hindering progress toward an HIV vaccine?

TED | The trials, tribulations and timeline of a COVID-19 vaccine

Wired Korea | The End of World War C: Peace without Victory?

Asian Boss | World’s Leading Vaccine Expert Fact-Checks COVID-19 Vaccine Conspiracy

Development Today | Why Sweden funds a vaccine institute in Korea and not Oslo-based CEPI

CNBC | Parts of Asia that relaxed restrictions without a resurgence in coronavirus cases did these three things

The Korea Herald | [Herald Interview] ‘Making vaccines accessible is biggest COVID-19 challenge’

CGTN: The Agenda with Stephen Cole | Speed of vaccine trials is ‘unprecedented’

Asian Boss | We Asked The World’s Leading Vaccine Expert About COVID-19 Vaccine

The Guardian | Test, trace, contain: how South Korea flattened its coronavirus curve

BBC World Service: The Inquiry | How do we come out of the lockdown? (13:00)

ANC 24/7 | Int’l Vaccine Institute: 12-18 months reasonable timetable for development of Covid-19 vaccine

Seeker | How Fast Can We Make a Coronavirus Vaccine?

Education City Speaker Series: Flattening the Curve – Global Responses to COVID-19

Wion News | About 70% of vaccines used around the world are made in India: S Korean expert Dr Jerome Kim

South China Morning Post | How long will a coronavirus vaccine take? A Q&A with Jerome Kim, head of the International Vaccine Institute

BBC World News | Jerome Kim: Vaccines are the long-term solution to the pandemic

The Korea Times | Developing vaccine against COVID-19

TRT: Bigger than Five | COVID-19: The World Reacts

South Korea’s fight against coronavirus (CBS News)

NDTV | Top South Korea Doctor On Why He Thinks Coronavirus Is Not A ‘Chinese Virus’

RTE | What South Korea can teach Ireland about fighting Covid-19

Physical distancing should last months, not weeks, says epidemiologist (Yahoo News Canada)

Development of vaccine requires massive investment… international cooperation is needed (Korea Economic Daily)

COVID-19 Pandemic (Arirang TV, 22:50~46:00)

By then, we’ll have a vaccine on our side (Hankyoreh—Korean)

Coronavirus Pandemic: International Vaccine Institute director on how long it will take to develop vaccine (CGTN)

Testing times: Why South Korea’s COVID-19 strategy is working (Al Jazeera English)

Genexine seeks to compress the vaccine timeline

Genexine, Binex to develop COVID-19 vaccine (Korea Biomedical Review)

Genexine, Binex to co-develop coronavirus vaccine GX-19 (Korea Herald)

How close are we to a COVID-19 vaccine? Jerome H. Kim from International Vaccine Institute (Arirang News)

COVID-19 vaccine, drugs on fast track for development: IVI chief (Yonhap News)

Inside the race to find a coronavirus vaccine (Devex)

Chinese students keen for turnaround (China Daily)

China Daily | S. Korea can try out makeshift hospitals, experts say

Director General Jerome Kim for Phoenix TV

Speed and accuracy vital for COVID-19 test kits (Arirang News)

2020 COVID-19 Live Updates: Jerome Kim for tbs eFM

Jerome Kim for KBS WORLD Radio, Korea24 on the COVID-19 outbreak in South Korea

Korea should join efforts in vaccine development to prevent pandemics (JoongAng Ilbo)

Future global health threats

IVI: COVID-19 could linger (Korean)

Jerome Kim for Korea, Factual: “Hong Kong’s handling of COVID-19 outbreak & Prospects of vaccine development”

Concerns about the spread of COVID-19: When will a vaccine be developed? When can we expect the “Super Vaccine”?

Al Jazeera English | Scientists call for global cooperation over coronavirus

When will COVID-19 vaccine be commercialized…And “super vaccine”? (Korean)

Global push to find vaccine against devastating bug growing

IVI receives $15.7 million to conduct Ph III trials of typhoid vaccine

Korean vaccines expanding global territory

Neglected Victims of Neglected Diseases

Let’s build a common defense against epidemics

Vaccine investment brings 16-fold return… partnering with Bill Gates

World must join forces to prevent infectious diseases

IVI editorial in The Korea Herald advocates for Korean leadership for global health

×

IVI and SK Chemicals Receive Funding to Advance Development of a New Typhoid Vaccine

Author
Margaret
Date
2014-12-22 00:00
Views
3677

 

IVI and SK Chemicals Receive Funding

to Advance Development of a New Typhoid Vaccine

  • IVI partnering with SK Chemicals on vaccine research and development
  • 4.9 million USD grant from Gates Foundation to support typhoid vaccine early clinical trials

 

SEOUL, SOUTH KOREA – The International Vaccine Institute (IVI) announced today that grant funding of 4.9 million USD was received from the Bill & Melinda Gates Foundation to support clinical research and development of a new typhoid fever vaccine in collaboration with SK Chemicals. The grant is effective from December 2014 to September 2017.

 

“We are very grateful for this grant from the Bill & Melinda Gates Foundation to enable us to take the first step toward the goal of collaboration between IVI and SK Chemicals.” said Mr. In-serk Lee, President of SK Chemicals. “Through collaboration, we believe that the strengths and expertise of IVI and SK Chemicals can be maximized to accomplish our goal of developing the typhoid vaccine on schedule.”

 

Typhoid fever is a systemic illness that is a public health problem among impoverished populations in developing countries. Spread by ingesting contaminated food or water, typhoid is found in settings where sanitation, hygiene, and clean water are limited. It is estimated to cause 160,000 to 170,000 deaths and 16 to 22 million cases annually. While vaccines and treatment for typhoid are available, current vaccines cannot protect children below two years of age, an age group considered more vulnerable to typhoid; and antibiotic treatments are becoming less effective and more costly due to increasing rates of antibiotic-resistant strains of typhoid.

 

IVI developed a new typhoid vaccine based on conjugation of the bacterial Vi polysaccharide antigen, conjugated to diphtheria toxoid (DT). Compared with current typhoid vaccines, it has the potential to protect children below two years old and to provide protection against typhoid for a longer duration of time. SK Chemicals has gained extensive technology and expertise on conjugate vaccines from its experience with the pneumococcal conjugate vaccine. By combining this with the technology transferred from IVI, SK Chemicals has successfully established the manufacturing process for the typhoid vaccine at a commercial scale.

 

In 2012, IVI and SK Chemicals signed a Memorandum of Understanding to collaborate on clinical development of the typhoid conjugate vaccine with the intent to attain prequalification by the World Health Organization (WHO); in which SK Chemicals has agreed to supply the vaccine at an affordable price for the public health sector worldwide. It will manufacture the vaccine at its brand new vaccine manufacturing facility located in Andong City, North Gyeongsang Province. Achievement of WHO prequalification indicates that the vaccine meets international standards in quality, safety and efficacy, and enables the vaccine to be purchased by UN agencies.  In 2013, IVI completed transfer of the vaccine production and quality control technology to SK Chemicals. Planning is ongoing for preclinical and phase 1 and 2 trials, which will commence in 2015. 

 

The new grant will support early clinical trials for the typhoid conjugate vaccine. IVI will work with SK Chemicals in the development and conduct of clinical trials for vaccine licensure and eventually WHO prequalification.

 

“We are extremely pleased to receive funding from the Gates Foundation to support the development of the typhoid conjugate vaccine in collaboration with SK Chemicals,” said John Morahan, IVI Acting Director General, “With firm support from the foundation and a prominent, trusted partner like SK Chemicals, we are confident that we will achieve our goal of creating a safe, effective, and affordable typhoid vaccine for low-income countries.”

 

 

About IVI

The International Vaccine Institute (IVI) is the world’s only international organization devoted exclusively to developing and introducing new and improved vaccines to protect the world’s poorest people, especially children in developing countries. Established in 1997, IVI operates as an independent international organization under a treaty signed by 35 countries and the World Health Organization. The Institute conducts research in more than 20 countries of Asia, Africa and Latin America on vaccines against enteric and diarrheal infections, Japanese encephalitis, and dengue fever, and develops new and improved vaccines at its headquarters in Seoul, Republic of Korea. For more information, please visit http://www.ivi.int.

 

 

About SK Chemicals

SK Chemicals is a research-focused company with a mission to provide total healthcare solutions from prevention to treatment. With a strong technological foundation and a wide range of products including vaccines, plasma products, value-added generics and novel chemical products, SK Chemicals has been expanding its horizon into the global pharmaceutical and vaccines market.

Specifically, with regard to the vaccine business, the Company has constructed a state-of-the-art vaccine manufacturing facility in Gyeongbuk Bio Complex in Andong, Republic of Korea, which is the first facility to hold a commercial-scale production process for the cell culture-based influenza vaccine in the country. SK Chemicals is also conducting the final phase of clinical studies for pneumococcal conjugate vaccine and chickenpox vaccine, as well as the shingles vaccine for global market.

  

Media Contact:

 

Tae Kyung Byun

Public Awareness/Advocacy Officer, IVI

Phone: +82-2-872-2801 (Ext. 159)     

Mobile: +82-11-9773-6071

Email: tkbyun@ivi.int

 

Sung-Woo Kim

Corporate & Public Relation/General Manager, SK Chemicals Co., Ltd.

Phone: +82-2-2008-2064

Email: jabbar33@sk.com

 

DONATE